Company Deep Dive
Read the full research report: business segments breakdown, earnings transcripts review, management credibility analysis, competitive landscape, and scenarios.
EXEL
Strong BuyAPPROVEExelixis, Inc. · Healthcare · United States · $13.5B · Avg Vol: $134M/d
Exelixis generates strong cash flow from its marketed kidney and liver cancer franchise, runs a large net-cash position and has executed sizeable buybacks, producing the strongest quality score in this batch (Q89) with firm momentum. It also resolved the key patent challenge to its lead product, extending the revenue runway. The trivial insider selling and marginal consensus trim are immaterial.
COMPANY DESCRIPTION
Exelixis, Inc. is a biotechnology company focused on the discovery, development, and commercialization of innovative small molecule therapies for cancer. Its competitive strength stems from its flagship oncology product, CABOMETYX, and a robust pipeline targeting various cancer indications, establishing it as a significant player in the oncology therapeutics market.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.6B | 1.8B | 2.2B | 2.3B | 12.9% | 2.4B | 2.6B | 2.9B | 11.2% |
| EPS | 0.56 | 0.65 | 1.80 | 2.88 | 72.6% | 3.18 | 3.35 | 3.89 | 16.2% |
| Shares | 324.0M | 302.8M | 281.7M | 262.5M | -19.0% | 247.8M | — | — | — |
| Debt | 190.2M | 189.9M | 190.8M | 173.0M | -3.1% | 165.9M | — | — | — |
| Equity | 2.5B | 2.3B | 2.2B | 2.2B | -4.6% | — | — | — | — |
| Op CF | 362.6M | 333.3M | 700.0M | 884.3M | 34.6% | 1.2B | — | — | — |
| Inv CF | -524.4M | -27.0M | -116.8M | 350.4M | — | — | — | — | — |
| Fin CF | 0.6M | -546.1M | -628.8M | -969.6M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of EXEL are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| EXEL | Exelixis, Inc.(you) | $13.5B | 99 | Strong Buy |
| HALO | Halozyme Therapeutics, Inc. | $12.0B | 95 | Strong Buy |
| INCY | Incyte Corporation | $25.2B | 96 | Strong Buy |
| CORT | Corcept Therapeutics Incorporated | $12.3B | 80 | Buy |
| TECH | Bio-Techne Corporation | $11.3B | 74 | Buy |
| KRYS | Krystal Biotech, Inc. | $10.4B | 73 | Buy |
| ACAD | ACADIA Pharmaceuticals Inc. | $5.0B | 81 | Strong Buy |
| HRMY | Harmony Biosciences Holdings, Inc. | $2.3B | 100 | Strong Buy |
| BMRN | BioMarin Pharmaceutical Inc. | $12.5B | 61 | Hold |
| LGND | Ligand Pharmaceuticals Incorporated | $5.6B | 73 | Buy |
Peer medians: ROE -25.9% · P/E 29.6x · Gross margin 58.7%